Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | HPGDS | O60760 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000542 | 0.72 | SCN9A (0.38) | HSD11B1SCN9AHPGDSDDB1CRBN | |
| SCHEMBL29975282 | 0.71 | HPGDS (0.41) | HSD11B1SCN9AHPGDSDDB1CRBN | |
| SCHEMBL29325904 | 0.71 | SCN9A (0.33) | HSD11B1SCN9AHPGDSDDB1CRBN | |
| SCHEMBL29325902 | 0.71 | SCN9A (0.33) | HSD11B1SCN9AHPGDSDDB1CRBN | |
| SCHEMBL29155912 | 0.71 | HPGDS (0.41) | HSD11B1SCN9AHPGDSDDB1CRBN | |
| SCHEMBL29326790 | 0.71 | HPGDS (0.38) | HSD11B1SCN9AHPGDSMKNK1MKNK2 | |
| SCHEMBL29326090 | 0.67 | PIM1 (0.42) | HSD11B1MKNK1MKNK2 | |
| SCHEMBL29326092 | 0.67 | IDH1 (0.44) | HSD11B1MKNK1MKNK2 | |
| SCHEMBL29326088 | 0.66 | HPGDS (0.34) | HPGDS | |
| SCHEMBL29155938 | 0.66 | HPGDS (0.34) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | HSD11B1 1433/4885SCN9A 3093/4885HPGDS 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.